Atogepant (MK-8031) 1374248-81-3

Atogepant More Info

Atogepant is a potent, orally administered, small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, specifically developed for the preventive treatment of migraine. Its development was a direct result of advanced research into the neurobiology of migraine, which identified the CGRP pathway as a critical mediator in the initiation and propagation of migraine attacks. Unlike earlier preventive treatments that were repurposed from other indications (such as cardiovascular or antidepressant drugs), atogepant was designed from the outset to target the migraine pathway specifically. This mechanism offers a more targeted approach to migraine prevention, representing a significant shift in therapeutic strategy. The compound is a synthetic molecule with a defined molecular weight and structure, meeting the high purity standards required for pharmaceutical use.

Uses and Applications

The sole and primary application of atogepant is in the field of neurology as a prophylactic (preventive) medication for episodic and chronic migraine in adults. It is not intended for the acute treatment of a migraine attack that has already started. By competitively blocking the CGRP receptors, it inhibits the biological activity of the CGRP neuropeptide, which is believed to play a pivotal role in causing the pain and associated symptoms of migraine. Its oral dosage form (tablet) allows for convenient once-daily administration, which can improve patient compliance compared to injectable or infusion-based therapies. Clinical trials have demonstrated its efficacy in significantly reducing the number of migraine days per month for a substantial proportion of patients.

Application Markets

Atogepant occupies a position in the highly specialized and valuable global market for migraine therapeutics, particularly within the preventive segment. This market has experienced considerable growth and innovation with the introduction of CGRP-targeted therapies. Its primary competitors are other CGRP monoclonal antibodies (injectables) and small molecule gepants. The target audience includes neurologists, headache specialists, and general practitioners who manage patients with debilitating migraine that requires preventive intervention. The market is predominantly concentrated in North America, Europe, and other developed regions with advanced healthcare systems, though its reach is expanding. As a branded prescription drug, its distribution is tightly controlled through pharmaceutical channels and pharmacy networks.

Handling and Regulatory Considerations

Atogepant is an active pharmaceutical ingredient (API) and must be handled exclusively by trained personnel in accordance with Good Manufacturing Practice (GMP) and laboratory safety protocols. As a fine powder, engineering controls should be used to prevent inhalation and minimize dust generation. Personal protective equipment, including gloves and safety glasses, is mandatory to avoid potential skin contact or accidental ingestion. It is strictly for use in the formulated drug product and is not for consumer or direct patient handling in its raw form. The final formulated drug product is available only by prescription and carries specific warnings and precautions, including the potential for hypersensitivity reactions and interactions with other medications, particularly strong CYP3A4 inhibitors. All handling and dispensing must adhere to the regulations set forth by health authorities like the FDA or EMA.

Package Image

FAQ

Q1. Can I get a free sample?

We can send you a samll free sample, and you only need to pay for the shipping cost.

Q2. What is the HyperChem payment term?

T/T in advance
LC at sight
DP at sight

Bank transfer

PayPal

Bitcoin...

Q3. What is HyperChem shipment policy?

Our policy is to strive for the quickest shipment time possible.

For ready stock samples, they are usually shipped within 3 working days after payment received.
For non-ready stock, please contact HyperChem sales team to negotiate.

Q4. What is HyperChem shipment term?

By Express  
FedEx  UPS  DHL  EMS                               
Fast: 3-7 days around, high cost, door to door service

By Air                                        
Suitable for more than 50kg 
Fast: 3-7 days, hight cost, port to port, professional broker needed 

By Sea
Suitable for more than 500kg      
Fast: 7-45 days, low cost, port to port, professional broker needed 

We will always attempt to utilize the quickest and most affordable way for customers to receive orders. And follow -up with customers via email for all shipment details as well as updated track information until it arrives without damage.

Q5. What HyperChem will provide after shipment?

For sample orders: 
After shipment is done, an timely email including:

1. Track details (Fedex /TNT/DHL/EMS Track number)
2. Packaging photo
3. COA, MSDS, etc
4. Dispatch date & Estimated arriving time
5. Shipping invoice

For commercial orders
A full set of shipment documents as well as package photos can be provided in scan-copy and original, to help customers complete the customs clearance process.

Company Profile

Established in 2013, Hyper Chem has exclusive tie-ups with leading manufacturers, supplying raw materials produced in GMP and ISO 9002 certified facilities, and provides high-quality ingredients and raw materials to cater to the requirements of our diverse range of clients.

Among them, our key client industrial sectors around the global are:

Pharmaceuticals
Nutrition Ingredients/ Dietary supplements
Cosmetic Ingredients
Food Ingredients
Veterinary API
Agriculture fertilizer
Custom Synthesis lab supply

HyperChem provides to its wonderful and honorable clients comprehensive purchasing and distribution services which ensure that we are delivering the right generic, raw, or customized product, make sure that we are delivering it at the right time, ensure that it is delivered in the specified amount, and in the right kind of packaging to clients and customers of all types of industries irrespective of their size of operation.